Maguire Bruce A
Department of Exploratory Medicinal Sciences, Pfizer Global Research and Development, MS 8118W-106, Groton Laboratories, Groton, CT 06340, USA.
Microbiol Mol Biol Rev. 2009 Mar;73(1):22-35. doi: 10.1128/MMBR.00030-08.
The assembly of bacterial ribosomes is viewed with increasing interest as a potential target for new antibiotics. The in vivo synthesis and assembly of ribosomes are briefly reviewed here, highlighting the many ways in which assembly can be perturbed. The process is compared with the model in vitro process from which much of our knowledge is derived. The coordinate synthesis of the ribosomal components is essential for their ordered and efficient assembly; antibiotics interfere with this coordination and therefore affect assembly. It has also been claimed that the binding of antibiotics to nascent ribosomes prevents their assembly. These two contrasting models of antibiotic action are compared and evaluated. Finally, the suitability and tractability of assembly as a drug target are assessed.
细菌核糖体的组装作为新型抗生素的潜在靶点正日益受到关注。本文简要回顾了核糖体在体内的合成与组装过程，着重强调了组装过程可能受到干扰的多种方式。将该过程与我们获取大量知识所依据的体外模型过程进行了比较。核糖体组分的协同合成对于其有序且高效的组装至关重要；抗生素会干扰这种协同作用，从而影响组装。也有人认为抗生素与新生核糖体的结合会阻止其组装。对这两种截然不同的抗生素作用模型进行了比较和评估。最后，评估了组装作为药物靶点的适用性和可操作性。
